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Abstract
Purpose The aim of this study is to assess autonomic function by analyzing heart rate
variability (HRV) at rest and during submaximal exercise in OSA patients and a nonOSA control group.
Methods Subjects were classified as OSA (n=10) or non-OSA (n=16) based on results
from an at-home sleep assessment. Height, weight, waist and neck circumferences, and
body composition were collected during the first visit for each subject. Physical activity
during the day and nocturnal movement were assessed over a period of 4 days, including
3 weekdays and 1 weekend day, using accelerometers. HRV and blood pressure were
recorded at rest (visit 2) and during a submaximal graded exercise test (visit 3). HRV
variables that were not normally distributed were log transformed before statistical
analysis. Independent samples t-tests were used to establish differences between groups.
Pearson correlations were calculated to determine relationships between OSA and HRV
in terms of age and BMI. If there was a significant correlation between variables and age
and/or BMI, then a repeated measures ANCOVA was used with age or BMI as the
covariate. If there was not a significant correlation, a repeated measures ANOVA was
utilized.
Results At rest, the OSA group had lower SDNN, RMSSD, and Total Power (p<0.05). A
higher LF-HF ratio was found in the control group than the OSA group during exercise
(p<0.05). LFnu and HFnu were trending towards significance, both higher in the OSA
group (p=0.066 and p=0.075, respectively) during exercise indicating that the OSA group
did not experience parasympathetic withdrawal. All subjects participate in about 30
minutes of moderate physical activity daily.

vi

Discussion Results suggest that the OSA population may have increased autonomic
dysfunction during exercise due to sympathetic dominance and a blunted parasympathetic
response during steady-state exercise. Potential mechanisms for autonomic imbalances
include decreased chemoreceptor and baroreceptor sensitivity. Further research with a
larger OSA sample group is necessary.

vii

Chapter 1
Introduction
Obstructive sleep apnea (OSA) is a sleep disordered breathing syndrome caused
by the complete collapse of the pharyngeal airway.1,2 Apneas are pauses in respiration
“associated with ongoing ventilatory effect” lasting at least ten seconds.1,3 Hypopneas are
decreases in airflow combined with at least a 4 percent decrease in oxygen saturation due
to a partial collapse of the pharyngeal airway.1 OSA affects about 3 to 7 percent of adult
males and 2 to 5 percent of adult females, totaling 15 million adult Americans.1,4 In older
adults over the age of 65, the prevalence of OSA increases 2-3 fold compared to middleaged adults between the ages of 30-64 years old.5 Even though 15 million adult
Americans have OSA, at least 85% of cases are undiagnosed.6 With the rise of obesity in
America, the number of people with OSA is increasing.7 Roughly 1 in 5 adults has at
least mild OSA and 1 in 15 adults have moderate or severe OSA.6
The severity of OSA is determined by the apnea-hypopnea index (AHI) which is
measured by the number of apneas or hypopneas (also known as an “event”) per hour of
sleep.2 According to the AHI scale: mild OSA is 5 to 15 events per hour, moderate OSA
is 15 to 30 events per hour, and severe OSA is greater than 30 events per hour.2 One is
diagnosed with OSA when he/she has at least five events per hour combined with
excessive daytime sleepiness.1 The most absolute way to diagnose OSA is the
polysomnography method. This method requires the patient to participate in an overnight
sleep study.6,8 The variables monitored and measured include the electroencephalogram,
electromyogram, electrocardiogram, snoring, and respiration—flow, effort, and oxygen
saturation.6 These variables yield the distribution of sleep states and severity of sleep-
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disordered breathing.9 Since polysomnography is an expensive method to detect OSA,
heart rate variability has been used to assesses autonomic function.6
Numerous studies have established known risk factors for developing OSA. The
most important and controllable risk factor is obesity.2,3,7,10 In the four-year follow-up
Wisconsin Sleep Cohort Study, it was found that a 10 percent increase in weight yielded
a six-fold increase in risk of developing OSA.5 Approximately 70 percent of people with
sleep apnea are also obese.3 Other risk factors include male gender, large neck
circumference, increased waist circumference and central body fat, and habitual
snoring.1,5,11 However, it should be noted that not everyone with OSA is male, obese,
tired, middle-aged, and snores.5 Anatomical risk factors include hypertrophic tonsils, high
modified Mallampati grade, narrowing of palate or oropharyngeal walls, mandibular
retrognathia (“overbite”), and small crico-mental space.11 Mallampati grade is a test that
examines what is visible when a subject opens their mouth. For example, whether or not
the tonsils, soft palate, and uvula are visible; if a subject receives a higher score, they are
more likely to experience airway obstruction.12 Crico-mental space is determined “using
a thin ruler to connect the cricoid cartilage to inner mentum. This line is then bisected
and the perpendicular distance to the skin of neck is measured.”13 There is also
inconclusive evidence that genetics, smoking, menopause, alcohol use before sleep, and
nighttime nasal congestion increase the risk of developing OSA.5
Common symptoms of people who develop OSA include loud and habitual
disruptive snoring, breathing pauses during sleep, unwarranted daytime sleepiness, sexual
dysfunction, and nocturnal choking and gasping.1,5 These symptoms have been related to
a rise in vehicular crashes, psychosocial problems, decreases in cognitive function, and a
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decrease in quality of life.5 Sleep apnea has also been linked to various cardiovascular
diseases including but not limited to hypertension, coronary artery disease, myocardial
infarction, congestive heart failure, and stroke.5 In addition, there have been associations
between OSA and diabetes and metabolic syndrome.2,5
The pathophysiology of OSA is complex and varies among patients. The most
common causes are deficient pharyngeal anatomy and unsteady upper airway dilator
muscle control while awake and asleep.1,3,14 When a person is awake, the upper airway
dilator muscles are activated and used for speech, breathing, and swallowing. During
sleep, the dilator muscles relax and are more likely to collapse.15 The collapsing of the
airway can be attributed to negative pressure in the airway and positive pressure outside
the airway.3 A study by Isono et al. found that patients with sleep apnea had smaller
pharyngeal airways and increased collapsibility compared to the control group.16
Increased negative intraluminal pressure and narrowing of the pharyngeal airway has also
been found to contribute to this pathophysiology.11 Another mechanism of OSA is the
nocturnal loss of lung volume that decreases the traction on the upper airway increasing
the collapsibility.1,17 This is caused by the excess fat around on the neck. Localized fat
around the neck may also contribute to increased metabolic demand and amplified
breathing effort.17 The lack of stability of the ventilatory control system may also cause
OSA by the partial or complete collapse of the pharyngeal airway.1 OSA
pathophysiology could derive from changing surface tension in the airway, arousal
threshold, and asynchronous timing of activation of upper airway compared to pump
muscles.1 The pathophysiology of OSA results in sympathetic overdrive impacting the
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autonomic nervous system.18 The decrease in autonomic function can be measured by
heart rate variability.
Obstructive sleep apnea is related to cardiovascular diseases. More specifically, in
patients with hypertension OSA is 30 to 83 percent higher, 12 to 53 percent higher in
those with heart failure, 30 to 58 percent higher in those with ischemic heart diseases, and
43 to 91 percent higher in patients who have had a stroke.19 OSA and cardiovascular
disease (CVD) do not necessarily have a causal relationship. However, OSA may hasten
the rate of progression of any CVD including hypertension. In a four-year follow up
study of the Wisconsin Sleep Cohort Study, researchers found a dose-response
relationship between sleep apnea and the occurrence of hypertension four years later.20,21
The vasoconstriction in the periphery is a result of an apnea. When the person is able to
breathe again, there is increased venous return and cardiac output against the
vasoconstricted periphery which causes a rise in blood pressure. It has been documented
that person without hypertension can reach up to 250/110 mmHg after an apnea.18 There
are numerous potential mechanisms that attribute OSA affecting CVD: vascular injury,
acceleration of atherosclerosis due to hypoxemia, chronic sympathetic hyperactivity,
hypertension, heart failure.14 The American Heart Association (AHA) proposes the
following potential mechanisms: sympathetic activation, cardiovascular variability,
vasoactive substances, inflammation, oxidative stress, endothelial dysfunction, insulin
resistance, thrombosis, and intrathoracic pressure.1
OSA causes a lack of oxygen in the body when one has an event which causes
autonomic dysfunction. Two primary mechanisms that cause this imbalance in the
autonomic nervous system include decreased baroreceptor sensitivity and increased
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chemoreceptor sensitivity. Baroreceptors detect changes in blood pressure and aim to
keep it within a normal range. When people with OSA experience hypoxia throughout
the night, blood pressure rises. This reoccurring cycle desensitizes the baroreceptors
which results in raising the detection level in which they perceive high blood pressure.22
As this level increases, the baroreceptors are more tolerant of higher blood pressures that
they once detected increasing the likelihood of hypertension in this population.22 Higher
blood pressure increases sympathetic activity causing an imbalance in the autonomic
nervous system. During hypoxia, chemoreceptors detect lack of oxygen and increased
carbon dioxide. This heightens the sympathetic nervous system resulting in increased
heart rate and breathing and vasoconstriction thereby increasing blood pressure.23
Reoccurring hypoxias increase the sensitivity of the chemoreceptors ultimately increasing
the initiation of sympathetic nervous system when oxygen desaturation is detected.23
Patients with OSA have decreased heart rate variability (HRV) and increased blood
pressure variability. The decreased heart rate variability is potentially the connecting
factor between OSA and CVD.1
HRV is the physiologic changing of the heart rate over time based on the
interaction between the sympathetic and parasympathetic nervous systems which
measures autonomic function.4,24 It is measured by the changes in variation from R-R
intervals and is caused by heart rate, blood pressure, and respiration rate.18,24-26 HRV is
influenced by the changes in the autonomic nervous system, caused by both internal and
external stimuli, on the sinoatrial node. Measuring autonomic nerve function within the
cardiovascular system can be done by monitoring HRV.4 In persons with OSA a decrease
in HRV is believed to represent a decrease in autonomic control.27 Abnormal adaptability
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in autonomic nerve function is detected by decreased HRV and may be associated with
diseases such as renal failure, liver insufficiency, diabetes, congestive heart failure, and
myocardial infarction.4 Narkiewicz et al evaluated cardiovascular variability in OSA
patients without CVD. The patients were divided into 3 groups: mild OSA, moderate to
severe OSA, and a control group. It was found that patients with moderate to severe OSA
had significantly shorter RR intervals, faster heart rate, increased sympathetic burst
frequency, and changing blood pressure.18 They concluded that “cardiovascular
variability is altered in patients with OSA, even in the absence of hypertension, heart
failure, or other disease states; and the degree of derangement in cardiovascular
variability may be linked to the severity of OSA.”18
HRV can be analyzed using time-domain and frequency-domain measures.28
Time-domain measures include the standard deviation of all NN or RR intervals (SDNN),
the square root of the mean of the sum of squares of differences between adjacent NN or
RR intervals (RMSSD), and the division of the number of interval differences of
successive NN intervals greater than 50ms by the total number of NN intervals
(pNN50).29-31 SDNN represents all cyclic components of variability. 29-31 RMSSD is the
estimate of all short term components of HRV.29-31 Frequency-domain measures include
total power, low frequency (LF), high frequency (HF), and the LF-HF ratio. The total
power is the variance of NN intervals over the time period analyzed.31 The HRV
spectrum is comprised of two parts: a LF band and a HF band. The HF band (0.15-0.4
Hz) represents the parasympathetic system; the LF band (0.04-0.15 Hz) is related to both
the parasympathetic and sympathetic systems.32 In a recent study, researchers compared
HRV between OSA patients and control subjects using data collected from
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electrocardiogram. The researchers found a higher LF power, a lower HF power, and a
higher LF-HF ratio in OSA patients compared to the control subjects.28 This supports the
evidence increased sympathetic activity and/or decreased parasympathetic activity in
people with OSA.28 In patients with OSA, a decrease in HRV has been found but there is
variance in the HRV among patients suffering from OSA. The HRV pattern may be
different depending on gender, obesity, OSA severity, duration of sleep, and oxygen
saturation levels.25
Many studies have evaluated the relationship between OSA and HRV. A study of
78 patients with suspected OSA participated in an overnight polysomnography in which
HRV was also measured. Those with severe OSA had an increased number of longer
accelerated beats and a decreased number of deceleration beats indicating the lack of
balance between accelerations and decelerations in heart rate.33 An increase in cardiac
sympathetic drive is seen in patients with OSA during resting wakefulness depicted by
faster heart rates.1 There is also an increase in the activity of the parasympathetic
nervous system in OSA patients during sleep which suggests that it is related to
mechanisms compensating oxygen saturation changes.25 In another study, it was found
that patients with severe OSA had a shorter R-R interval during the night.24 OSA and
blunted HRV are both risk factors for cardiovascular disease which may cause
mortality.27 In comparison to similar obese control subjects, awake OSA patients at rest
have decreased HRV and increased blood pressure variability.1 Unfavorable outcomes
are expected in those with cardiovascular disease and diminished HRV.1 According to
the Framingham Heart Study, lower HRV is a risk factor to the development of
hypertension and increased blood pressure variability has been associated with a higher
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risk of organ damage in those with cardiovascular disease.1 In the Wisconsin Sleep
Study, a relationship between OSA and hypertension was confirmed.2 OSA patients are
more likely to develop coronary artery disease, cerebrovascular disease, atherosclerosis,
arterial stiffness, cardiac arrhythmias, and heart failure.2
It is still unknown as to whether or not OSA limits exercise capacity. It can be
assumed that because people with OSA have increased daytime sleepiness, there would
be a decreased desire to engage in physical activity and are more exhausted at a given
workload.34 The combination of unwarranted daytime sleepiness and fatigue could
potentially impact the difficulty of exercise for people with OSA. Levels of fatigue may
be increased at lower intensity exercise due to the overloading of dilator muscles after an
apnea occurs.35 Studies have observed the impact that exercise training has on the
severity of OSA. A meta-analysis by Iftikhar et al. examined the effectiveness of
exercise training in OSA patients in terms of severity, BMI, sleep efficiency, daytime
sleepiness, and cardiovascular fitness.36 Interestingly, the researchers found that despite
changes in BMI and body weight, exercise does have a significant effect on AHI.36
Exercise training was able to decrease the severity of the patients’ OSA.
As previously mentioned, OSA increases the risk for developing CVD including
faster heart rate, longer heart rate recovery period, longer QT-interval, and longer P-wave
duration.37 Longer P-wave and QT-interval durations increase the likelihood of an
abnormal heart rhythm. There is a four-fold increase for atrial fibrillation if a patient has
severe OSA at rest.37 The question then arises whether or not exercise is safe for people
with OSA. During exercise there is a higher risk for experiencing an abnormal heart rate
or rhythm. Exercise increases sympathetic activity and number of circulating
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catecholamines potentially causing increased abnormal automaticities and related
premature beats.38 Arrhythmias are also common in people with OSA. For example, the
risk for ventricular tachycardia, second degree atrioventricular block, and premature
ventricular contractions is higher in the OSA population.39,40 An increased resting heart
rate and cardiovascular events have shown to be associated in many studies although
“few studies have looked at the impact of OSA on HR.”37 Investigating this impact will
give greater insight into how the autonomic nervous system responds to exercise when it
is altered because of OSA. It is unknown whether acute exercise would increase the
likelihood of a patient with untreated OSA to have abnormal heart rhythms and if
exercise would be safe for this population.
Purpose:
This study analyzed HRV at rest and during submaximal exercise in OSA patients and a
control group.
Hypothesis:
We hypothesized that during exercise, autonomic function measured via HRV would be
blunted in OSA patients as compared to a control group.
Limitations:
Subjects often overestimated or underestimated their physical activity levels.
Delimitations:
Subjects had a body mass index of at least 25 kg/m2.
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Subjects who were using medications that may influence heart rate were excluded from
this study.
Subjects did not have any cardiovascular, pulmonary, or metabolic diseases.

Chapter 2
Methodology
Participants
The researchers recruited twenty persons with obstructive sleep apnea (OSA)
from James Madison University and the Rockingham Memorial Hospital Center for
Sleep Medicine in Harrisonburg, Virginia. In addition, a non-OSA control group was
recruited. Inclusion criteria for subjects included males and females at least eighteen
years old with a minimum BMI of 25 kg/m2. Exclusion criteria for subjects included
known cardiovascular disease, congestive heart failure, or pulmonary disease, and being
in the “high risk for atherosclerotic cardiovascular disease” category as defined by the
American College of Sports Medicine.41 The International Physical Activity
Questionnaire Short Form (IPAQ) was used to exclude those who were highly physically
active in order to eliminate the potential influence of regular physical activity on the
study’s outcomes. Any persons taking medications that could potentially influence heart
rate and HRV were also excluded. Participants were asked to report to the Human
Performance Laboratory (HPL) in Godwin Hall at James Madison University on three
separate occasions for a total of two and a half hours. All procedures were approved by
the JMU Institutional Review Board (IRB).
Visit 1
Before the testing began, all subjects completed a health history questionnaire
(HHQ) in order to provide basic health information and to identify any potential
exclusion criteria as well as three additional questionnaires. The Berlin Questionnaire
(BQ) and the Screening Tool for OSA (STOP) Questionnaire were used to establish risk
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factors for OSA and their level of snoring, and the Epworth Sleepiness Scale (ESS) was
used to establish daytime sleepiness levels.
Body Mass and Height
Subjects had their body weight and height measured using a physician’s scale and
stadiometer, respectively. The subjects removed their shoes, excess/layered clothing, and
any items in their pockets before stepping on to the scale. Body weight was measured to
the nearest 0.5 lbs and converted to kilograms. Height was measured with a stadiometer
to the nearest 0.5 cm. Waist and neck circumferences measurements were taken using a
cloth tape measure with a spring-loaded handle to reduce the compression of the skin.
The waist circumference was measured directly above the subject’s iliac crest. The neck
circumference was measured around the widest part of the subject’s neck.
Anthropometry and Body Composition
Body composition was analyzed using a Dual-Energy X-Ray Absorptiometer
(Lunar iDXA 1RME+200072 (14.10), Madison, Wisconsin). The scan consists of total
body/visceral fat and bone mineral density. The subject was symmetrically centered
within the white outer lines on the bed with their spine and head along the center line. If
the subject could not fit within the white box, he or she was adjusted so that their entire
right side fit within the box. The DEXA is capable of estimating total body fat based on
a scan of one side of the body.
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At-Home Sleep Assessment
The ApneaLinkTM (ApneaLinkTM Plus, San Diego, California) was used to screen
for the presence of OSA. The research staff thoroughly explaind to the participants how
to setup and use the ApneaLinkTM at-home screening device. When subjects returned the
ApneaLinkTM the following day, the data collected by the device was downloaded using
the ApneaLinkTM software. The software analyzed the number of events per hour the
subject had as well as the amount of snoring, oxygen saturation levels, and sleep latency.
A certified sleep technician and sleep physician reviewed the sleep data collected by the
ApneaLinkTM. In addition, subjects were given an accelerometer (ActiGraph, GT3XPlus, Pensacola, Florida) to assess nocturnal movement. The ActiGraph is a small device
worn on their non-dominant wrist during sleep and was attached to a watch in order to
prevent insignificant movement of the accelerometer. Participants were instructed to
record the times that they went to bed and the time they got out of bed on a log sheet and
to note any abnormalities that may have occurred during sleep. The ActiGraph was worn
for 4 days including 3 weekdays and 1 weekend day.
Physical Activity Assessment
The ActiGraph accelerometer was also utilized to assess the subjects’ daily
physical activity levels. Subjects wore the accelerometer on the waistband of their right
waist line mid-thigh. Subjects were asked to continue their normal daily activities and to
document any abnormal physical activities. After the four days of physical activity
assessment, subjects returned the accelerometer device to the HPL, and continued with
Visit 3 procedures.
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Visit 2
Heart Rate Variability Assessment
Each subject completed HRV measurements, heart rate, and blood pressure
measurements at rest. Heart rate and HRV were measured using a Polar RS800CX
monitor (Kempele, Finland). The monitor’s data was saved to the Polar watch which was
downloaded using the Polar Pro Training 5 software. Subjects laid supine in a darkened
room while the heart rate and HRV were monitored over a 15 minute time period. In
addition, resting hemodynamic values was assessed using a non-invasive bioimpedance
device (PhysioFlow FP-05 Lab 1, NeuMeDx, Bristol, Pennsylvania). Subjects were asked
to breathe in synchronization with a metronome at 12 beats per minute to control for the
effect of respiration on the HRV variables.
The HRV variables are based on frequency or time-domain. Frequency based
variables include total power (TP), LF, HF, and LF-HF ratio. TP (msec2) measures the
energy in the heart from 0 to .40 Hz.42 LF (msec2) is the energy in the heart from 0.04 to
0.15 Hz. There is numerous controversial research stating that LF does not solely
represent sympathetic activity but also represents parasympathetic drive.29,30 According
to Massimo Pagani’s research group, the LF component shows cardiac sympathetic
flow.30 HF (msec2) is the energy in the heart from 0.15 to 0.40 Hz and represents
parasympathetic activity. Malliani, Lombardi, and Pagani found in healthy human
subjects and animal experiments, the LF factor of heart rate and arterial pressure
variability was increased by moderate hypotension, physical activity, and the occlusion of
the coronary or carotid arteries.43 The increase in the LF factor was accompanied by a
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decrease in the HF factor. The HF factor of HRV was increased in humans by controlled
respiration, cold stimulation of the face, and rotational stimuli.43 The LF-HF ratio is
simply the ratio between the LF and the HF power and reflects sympathovagal balance.42
The ratio also shows the relative sympathetic input of the control of one’s heart rate.30
The time domain variables include pNN50, SDNN, and rMSSD. pNN50 is a percentage
of differences between consecutive R-R intervals greater than 50 msec. SDNN (msec) is
the standard deviation of all normal R-R intervals during the recording and is related to
total power. rMSSD (msec) is the square root of the mean of the squares of differences
between consecutive R-R intervals and reveals parasympathetic activity.42
Resting Blood Pressure
Seated blood pressure was measured after the resting HRV assessment via
auscultation.
Visit 3
Submaximal Exercise Test
Subjects completed a two-stage, sub-maximal graded exercise test on the
treadmill. Before the exercise test, maximal fitness level (VO2max) was predicted using a
validated regression equation based on age, gender, physical activity status, and BMI.42
The treadmill speed was set to 3.5 miles per hour; the incline was individually adjusted
based on predicted VO2max corresponding to a light intensity (35% VO2 reserve41) and a
vigorous intensity (70% VO2 reserve41). Subjects walked for a period of five minutes at
each intensity level. Heart rate and HRV were continuously monitored throughout the
exercise test and recovery with the Polar RS800CX monitor. Blood pressure was also
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monitored at each stage and during exercise recovery. Similar to resting hemodynamic
values obtained during visit 2, cardiovascular hemodynamic variables were obtained
throughout exercise and recovery using the PhysioFlow and a Metabolic Cart (Parvo
Medics True One 2400 Metabolic Measurement System, Sandy, Utah). Exercise tests
were terminated if subjects reach 85% of their predicted maximal heart rate reserve in
accordance with the published ACSM guidelines for sub-maximal exercise tests.41 The
test was also terminated if any subjects had contraindications during the exercise test
published in the ACSM guidelines.41,44
Statistics
Statistical analysis was performed using SPSS. Subject characteristics were
reported as means ± standard deviation. Statistical significance was set at p < 0.05. HRV
variables that were not normally distributed were log transformed before statistical
analysis. Normalized LF (LFnu) was calculated as LFnu = LF/(TP-VLF)*100 and
normalized HF (HFnu) was calculated as HFnu = HF/(TP-VLF)*100. Independent
samples t-tests were utilized to identify baseline differences between the OSA group and
control group. Pearson correlations were calculated to determine relationships between
age and BMI. If a significant effect of age or BMI was observed, then an analysis of
covariance (ANCOVA) was used with an adjustment. If the effect of age or BMI was not
significant, then a repeated measures analysis of variance (ANOVA) was used without
adjustment.

Chapter 3
Manuscript
The Effects of Obstructive Sleep Apnea (OSA) on Autonomic Function
during Steady-State Exercise
Abstract
Purpose The aim of this study is to assess autonomic function by analyzing heart rate
variability (HRV) at rest and during submaximal exercise in OSA patients and a nonOSA control group.
Methods Subjects were classified as OSA (n=10) or non-OSA (n=16) based on results
from an at-home sleep assessment. Height, weight, waist and neck circumferences, and
body composition were collected during the first visit for each subject. Physical activity
during the day and nocturnal movement were assessed over a period of 4 days, including
3 weekdays and 1 weekend day, using accelerometers. HRV and blood pressure were
recorded at rest (visit 2) and during a submaximal graded exercise test (visit 3). HRV
variables that were not normally distributed were log transformed before statistical
analysis. Independent samples t-tests were used to establish differences between groups.
Pearson correlations were calculated to determine relationships between OSA and HRV
in terms of age and BMI. If there was a significant correlation between variables and age
and/or BMI, then a repeated measures ANCOVA was used with age or BMI as the
covariate. If there was not a significant correlation, a repeated measures ANOVA was
utilized.
Results At rest, the OSA group had lower SDNN, RMSSD, and Total Power (p<0.05). A
higher LF-HF ratio was found in the control group than the OSA group during exercise
(p<0.05). LFnu and HFnu were trending towards significance, both higher in the OSA
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group (p=0.066 and p=0.075, respectively) during exercise indicating that the OSA group
did not experience parasympathetic withdrawal. All subjects participate in about 30
minutes of moderate physical activity daily.
Discussion Results suggest that the OSA population may have increased autonomic
dysfunction during exercise due to sympathetic dominance and a blunted parasympathetic
response during steady-state exercise. Potential mechanisms for autonomic imbalances
include decreased chemoreceptor and baroreceptor sensitivity. Further research with a
larger OSA sample group is necessary.
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Introduction
Obstructive sleep apnea (OSA) is a sleep disorder characterized by the partial
and/or complete collapse of the pharyngeal airway in addition to excessive daytime
sleepiness.1,2 An apnea occurs when there is a total collapse of the pharyngeal airway
lasting at least ten seconds.1,3 A partial collapse airway combined with at least a 4
percent decrease in oxygen saturation is referred to as a hypopnea.1 OSA affects
approximately 15 million adult Americans1,4; however, it is estimated that at least 85% of
cases are undiagnosed.5 In adults over the age of 65, the prevalence increases two-tothree fold compared to adults between the ages of 30-64 years old.6 With the rise of
obesity in America, the number of people with OSA is likely increasing.7 This disorder
has been found to be related to a rise in vehicular crashes, psychosocial problems,
decreases in cognitive function, and a decrease in quality of life.6 This syndrome has also
been linked to various cardiovascular diseases such as hypertension, coronary artery
disease, myocardial infarction, congestive heart failure, and stroke.6
The most common and controllable risk factor for OSA is obesity.2,3,7,8 Roughly
70% of people with sleep apnea are also obese.3 Other risk factors include male gender,
large neck circumference, increased waist circumference, habitual snoring, and upper
airway structural abnormalities.1,6,9 Structural abnormalities include enlarged tonsils,
narrowing of palate or oropharyngeal walls, and mandibular retrognathia.9 There is
inconclusive evidence that genetics, smoking, menopause, alcohol use before sleep, and
nighttime nasal congestion increase the risk for developing OSA.6
The pathophysiology of OSA is complex and varies among patients. The most
common causes of are deficient pharyngeal anatomy and unsteady upper airway dilator
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muscle control while awake and asleep.1,3,10 During wakefulness, a person is in control
of their dilator muscles as they are used for speech, breathing, and swallowing. During
sleep, the dilator muscles relax and are more likely to collapse.11
The pathophysiology mechanisms of OSA result in sympathetic overdrive
impacting the autonomic nervous system.12 Two potential mechanisms that cause this
imbalance in the autonomic nervous system include decreased baroreceptor sensitivity
and increased chemoreceptor sensitivity. Baroreceptors detect changes in blood pressure
and aim to keep it within a normal range. When people with OSA experience hypoxia
throughout the night, blood pressure rises. This reoccurring cycle desensitizes the
baroreceptors which results in raising the “set point” or level in which they detect the
high blood pressure.13 As this level increases, the baroreceptors are less sensitive to the
higher blood pressures.13 When the baroreceptors become desensitized, a rise in blood
pressure is not countered by a reduction in sympathetic activity, thereby contributing to
an autonomic imbalance. During hypoxia, chemoreceptors detect lack of oxygen and
increased carbon dioxide. This heightens the sympathetic nervous system resulting in
increased heart rate, breathing, and vasoconstriction thereby increasing blood pressure.14
Reoccurring hypoxias increase the sensitivity of the chemoreceptors ultimately increasing
the initiation of sympathetic nervous system when oxygen desaturation is detected.14
Additionally, patients with OSA also have faster heart rates while awake, potentially
signifying a heightened sympathetic nervous system.1 The aroused sympathetic nervous
system in people with sleep apnea creates an imbalance in the autonomic nervous system,
specifically between the sympathetic and parasympathetic nervous systems. The
decrease in autonomic function can be measured by heart rate variability (HRV).
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HRV is the physiologic changing of the heart rate over time based on the
interaction between the sympathetic and parasympathetic nervous system.4,15 It is
measured by the changes in variation from R-R (also known as N-N) intervals and is
caused by heart rate, blood pressure, and respiration rate.12,15-17 A decrease in autonomic
control may be associated with diseases such as renal failure, liver insufficiency,
diabetes, congestive heart failure, and myocardial infarction.4 Patients with moderate to
severe OSA have significantly shorter R-R intervals, faster heart rate, increased
sympathetic burst frequency, and changing blood pressure.1,12,15
Although the relationship between OSA and HRV has been studied in both awake
and asleep patients at rest, the relationship has not been examined during a bout of acute
exercise. Previous research has investigated autonomic function during exercise in
untreated OSA subjects measured by heart rate and blood pressure recovery.18 The study
found a decreased heart rate response in the OSA group during the recovery period
suggesting autonomic dysfunction.18 Other studies have similarly found a decreased or
blunted response in heart rate recovery after a bout of exercise.19-21
It is also known that during exercise there is a higher risk for experiencing an
abnormal heart rate or rhythm. Exercise increases sympathetic activity and number of
circulating catecholamines potentially causing increased automaticities and related
premature beats.22 Arrhythmias are also common in people with OSA. For example,
there is a four-fold increase for atrial fibrillation if a patient has severe OSA23 and the risk
for ventricular tachycardia, second degree atrioventricular block, and premature
ventricular contractions is higher in the OSA population.24-26,27,28 The question then
arises whether or not exercise is safe for people with OSA. An increased resting heart
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rate and cardiovascular events have shown to be associated in many studies although
“few studies have looked at the impact of OSA on HR.”23 Investigating this impact will
give greater insight into how the autonomic nervous system, measured directly by HRV,
responds during an exercise session when it is altered because of OSA. To date, no one
has utilized HRV variables during exercise to further consider the autonomic dysfunction
in OSA patients. It is unknown whether acute exercise would increase the likelihood of a
patient with untreated OSA to have abnormal heart rhythms and if exercise would be safe
for this population. Therefore, the purpose of this study is to analyze HRV at rest and
during submaximal exercise of OSA patients and a control group.
Methods
Participants
Twenty-six (26) people from the Harrisonburg, Virginia community, including
James Madison University (JMU) and the Sentara Rockingham Memorial Hospital
(RMH) Center for Sleep Medicine, were recruited for this study. Subjects were all at
least 18 years old with at least a BMI of 25 kg/m2. Exclusion criteria included known
cardiovascular disease, congestive heart failure, or pulmonary disease, and being in the
“high risk for atherosclerotic cardiovascular disease” category as defined by the
American College of Sports Medicine (ACSM).29 Any persons taking medications that
could potentially influence heart rate and HRV were also excluded. Highly active
individuals (≥3 days of endurance exercise) and people who have received treatment for
OSA were excluded from the study. Subjects were asked to report to the Human
Performance Laboratory at James Madison University on three separate occasions within
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a one week time period. All procedures have been approved by the JMU and Sentara
RMH Institutional Review Boards.
Visit 1
Questionnaires
Before testing began, all subjects completed the consent form and several
questionnaires. Subjects completed a health history questionnaire to establish risk factors
described in the ACSM guidelines.29 The Berlin Questionnaire and the Screening Tool
for OSA (STOP) Questionnaire were used to establish risk factors for OSA and their
level of snoring. The Epwoth Sleepiness Scale (ESS) determined their level of daytime
sleepiness. The International Physical Activity Questionnaire Short Form was used to
establish a baseline for each subject’s physical activity level.
Anthropometry and Body Composition
All subjects had their body weight using a physician’s scale and height measured
using a stadiometer. Body weight was recorded to the nearest 0.1 lbs and converted to
kilograms; height was recorded to the nearest 0.25 cm. Waist, hip, and neck
circumferences were measured and followed the procedures described in the ACSM
guidelines.29 Measures of total and regional body composition were measured using a
dual-energy a-ray absorptiometer (Lunar iDEXA 1 RME+200072 (14.10), Madison,
Wisconsin).
At-Home Sleep Assessment
Subjects wore the ApneaLinkTM (ApneaLinkTM Plus, San Diego, California) for
one night in order to screen for the possible presence of OSA. Data collected from the
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ApneaLinkTM include the AHI, snoring patterns, oxygen saturation levels, sleep latency,
apneas, and hypopneas. The OSA group had an AHI ≥ 5; the control group had an AHI <
5. Subjects also wore a wrist accelerometer (ActiGraph, GT3X-Plus, Pensacola, Florida)
for 4 nights (3 weeknights and 1 weekend night) on their non-dominant wrist to assess
nocturnal movement. Participants recorded the times that they went to bed and the time
they got out of bed on a log sheet and to note any abnormalities that may have occurred
during sleep.
Physical Activity Assessment
An accelerometer was worn on each subject’s waistband of their right waist line
mid-thigh for 4 days (3 weekdays and 1 weekend day). Subjects reported anytime they
did not wear the device, planned bouts of exercise, and any abnormal physical activities.
The accelerometer measures activity based on movement counts per minute.30 The
number of movement counts per minute determines the subject’s intensity. The amount
of time spent at the various intensity levels is reported in table 2. Variables measured
from the accelerometer include the following: the number of sedentary bouts and the
duration of each bout; the amount of time spent being sedentary, participating in light,
lifestyle, moderate, vigorous, and very vigorous physical activity; and the number of
steps per day.
Visit 2
Heart Rate Variability Assessment
Heart rate and HRV were measured using a Polar RS800CX monitor (Kempele,
Finland). The monitor’s data was saved to the Polar watch which was downloaded using
the Polar Pro Training 5 software. Subjects were asked to lie supine in a darkened room

25

while the heart rate and HRV were monitored over a 15 minute time period. In addition,
each subject’s resting blood pressure was measured according to the ACSM procedures.29
Subjects were asked breathe in synchronization with a metronome at 12 beats per minute
to control for the effect of respiration on the HRV variables.
The HRV variables are based on frequency or time-domain. Frequency based
variables include total power, low frequency (LF), high frequency (HF), and LF-HF
ratio.31 Total power is the variance of NN intervals over the time period analyzed (2
minutes for this study).32 The LF and HF bands form the HRV spectrum. The HF band
(0.15-0.4 Hz) represents the parasympathetic system; the LF frequency band (0.04-0.15
Hz) is associated with both the parasympathetic and sympathetic systems.33 There are
three time domain variables. The first is the standard deviation of all the NN intervals
(SDNN).32,34,35 rMSSD is the square root of the mean of the sum of the squares of
differences between adjacent NN intervals—estimate of all short term components of
HRV.32,34,35 pNN50 is the division of NN50 (the number of interval differences of
successive NN intervals greater than 50ms) by the total number of NN intervals.32,34,35
Visit 3
Subjects completed a two-stage, submaximal graded exercise test on the treadmill.
Before the exercise test, maximal fitness level (VO2max) was predicted using a validated
regression equation based on age, gender, physical activity status, and BMI.31 The
treadmill speed was set to 3.5 miles per hour unless the subject could not tolerate this
speed, then it was set to 3.0 miles per hour. The incline was individually adjusted based
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on the predicted VO2max corresponding to a light intensity (35% VO2 reserve29) and a
vigorous intensity (70% VO2 reserve29).
Subjects walked for five minutes at each intensity while heart rate, HRV, blood
pressure, and ratings of perceived exertion variables were obtained. Tests were
terminated if any subjects had any contraindications during the exercise test as published
in the ACSM guidelines.29,36
Statistical Analysis
Statistical analysis was performed using SPSS. Subject characteristics are
reported as means ± standard deviation. Statistical significance was set at p < 0.05. HRV
variables that were not normally distributed were log transformed before statistical
analysis. Normalized LF (LFnu) was calculated as LFnu = LF/(TP-VLF)*100 and
normalized HF (HFnu) was calculated as HFnu = HF/(TP-VLF)*100. Independent
samples t-tests were utilized to identify baseline differences between the OSA group and
control group. Pearson correlations were calculated to determine relationships between
age and BMI. If a significant effect of age or BMI was observed, then an analysis of
covariance (ANCOVA) was used with an adjustment. If the effect of age or BMI was not
significant, then a repeated measures analysis of variance (ANOVA) was used without
adjustment.
Results
Baseline Characteristics
Twenty-six subjects were divided into two groups based on their AHI value.
Subject characteristics are presented in Table 1. The OSA group was significantly older
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than the control group. In addition, the OSA group had a significantly larger BMI, neck
circumference, and waist circumference. Sleep efficiency was significantly reduced in
the OSA group (p = 0.013); there were no differences in any other sleep quality variables
(Table 3). BMI significantly correlated with average length of awakening (r = 0.55, p =
0.005). This was the only variable that significantly correlated with BMI; therefore no
other variables were adjusted. There were no differences in physical activity between the
OSA and control groups (Table 2). The subjects averaged 30 minutes of moderate
physical activity each day (30 ± 16.8 minutes), thus meeting the ACSM guidelines.37 On
average, all subjects participated in physical activity 5 ± 0.71 days/ week. No subjects
engaged in very vigorous activity. Subjects walked 5481 ± 2200 steps/day.
Oxygen Consumption
There were significant differences between predicted oxygen consumption
between the OSA and control groups (p<0.05) as seen in Table 4 which can be attributed
to the age difference between groups. However, there were no differences between
groups for oxygen consumption, respiratory exchange ratio (RER), and systolic blood
pressure at either intensity (Table 4). There was a trend for diastolic blood pressure to be
higher in the OSA group with exercise, but it did not reach statistical significance
(p=0.067). Both groups had a significantly higher oxygen consumption (VO2) at both
intensities than predicted VO2 as seen in Table 4 (p<0.001).
Heart Rate Variability
Resting HRV data is shown in Table 5. SDNN, RMSSD, and TotalPower were
significantly lower in the OSA group compared to the control group (p<0.05). There
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were no group differences in HF and LF. There was a significant main effect for age in
both HF (p=0.027) and LF (p=0.041). An ANCOVA was used for HF and LF with age
as the covariate.
Exercise HRV data is presented in Table 5. During exercise, there was a
significant main effect for intensity, as SDNN and HF decreased as the intensity
increased. There was no main effect for group. During exercise, there was a significant
main effect for intensity, as RMSSD and LF increased as the intensity increased. There
was no main effect for group. For LFnu and HFnu there was no main effect for intensity,
but there a trend towards a main effect for group with the OSA group higher (p=0.066
and p=0.075 for LFnu and HFnu, respectively) (Figure 1A and 1B). There was no
significant main effect for intensity for LF-HF ratio; however, there was a significant
main effect for group. The OSA group had a significantly lower LF-HF ratio compared
to the control group (Figure 1C).
Discussion
This study confirms the findings of previous research on the autonomic function
of the OSA population at rest. During rest we saw lower values in SDNN, total power
(TP), and RMSSD in the OSA group indicating overall decreased HRV in this
population. SDNN represents a general picture of HRV, with a lower SDNN indicating a
lack of balance between sympathetic and parasympathetic activity or an autonomic
dysfunction38 A lower SDNN further suggests that the body is unable to maintain
homeostasis in the presence of internal and external stressors.39 A lower TP variable also
shows a decrease in total HRV, again providing evidence of autonomic dysfunction in
people with OSA. The OSA group also had lower RMSSD at rest indicating either vagal
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withdrawal, sympathetic dominance, or a combination of both.40 The autonomic
dysfunction at rest in this population is seen by increased sympathetic activity and
decreased parasympathetic activity.41 These resting HRV findings are in agreement with
several studies.41-44
A unique and major finding in our study was that during steady-state exercise
HFnu (i.e. parasympathetic activity) in the OSA group did not change significantly
between rest and exercise (Figure 1B). Moreover, the significant reduction in the LF-HF
was at least partially attributable to the unchanged HFnu (Figure 1C). The initial increase
from rest to light intensity in the LF-HF ratio during can be attributed to vagal
withdrawal rather than sympathetic stimulation.45 The decrease in the ratio from light to
vigorous intensity was expected since the balance between the sympathetic and
parasympathetic systems decreases in proportion to the exercise intensity (Figure 1C).45
The OSA group had a significantly lower LF-HF ratio during exercise (Table 5, Figure
1C). The LF-HF ratio represents the balance between the sympathetic and
parasympathetic systems.38 A higher LF-HF ratio would indicate increased sympathetic
dominance, while a lower LF-HF ratio would indicate an increased parasympathetic
dominance.39 The lower LF-HF ratio in the OSA group could potentially be explained by
the HFnu variable during steady-state exercise. The HFnu did not change between rest
and vigorous intensity in the OSA group (Table 5, Figure 1B). In a normal, healthy
individual during early exercise, there is vagal withdrawal and increased sympathetic
activity ultimately increasing the individual’s heart rate.45,46 As exercise duration
continues and intensity increases, sympathetic activity also increases.45,46 In this study,
as expected, the control group decreased HFnu with exercise due to vagal withdrawal and
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sympathetic excitation. Parasympathetic activity did not change significantly among the
three conditions in the OSA group. The lack of parasympathetic withdrawal could be the
link to autonomic dysfunction in this population.
During exercise, the OSA group was trending towards a higher main effect for
group in terms of HFnu (p=0.075, Table 5, Figure 1B). This indicates a lack of
parasympathetic response during exercise in the OSA group. Though the difference at
rest is not statistically significant, it may suggest that people with OSA inherently have a
lower level of parasympathetic activity. The OSA group was trending towards a
significantly higher main effect for group in terms of LFnu (p=0.066, Table 5, Figure
1A). This is in agreement with previous literature since people with OSA have
sympathetic dominance.44 Alameri et al. attributed increases in blood pressure and heart
rate and delayed return to resting heart rate in an OSA group during a 6 minute walk test
to sympathetic overdrive and delayed parasympathetic activity.47 The increase in
breathing frequency and tidal volume that occurs during exercise may have been
accelerated in the OSA group which would result in higher HFnu values compared to the
control group.48 The lack of parasympathetic withdrawal may cause the decreased HRV
by not allowing the heart rate to vary as much during exercise. This could be the link to
autonomic dysfunction in this population.
Potential mechanisms for the autonomic dysfunction in the OSA population
include the decreased baroreceptor sensitivity and heightened chemoreceptor sensitivity.
Baroreceptors are part of a homeostatic mechanism to keep blood pressure regulated. If
blood pressure increases, the baroreceptors send signals to the brain to decrease
sympathetic activity. This primarily slows down the heart and dilates the blood vessels
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ultimately allowing for the blood to flow through the vessels with less pressure.49
Repetitive hypoxias that occur in people with OSA cause increases in blood pressure. In
the presence of hypoxias and constant blood pressure variability, the baroreceptors
become desensitized to higher pressures.13,40 This decreased sensitivity in these receptors
increases likelihood of increased sympathetic activity and hypertension in this
population.14,50 Chemoreceptors are also very important in people with OSA since they
detect decreases in oxygen saturation.51 When these receptors sense oxygen desaturation,
the sympathetic nervous system is heightened and constricts vessels thereby increasing
blood pressure. 14,42,51-54 The actions of both baroreceptors and chemoreceptors cause
increases in sympathetic activity and related autonomic dysfunction in people with
OSA.13,14
One limitation in the study was the small sample size. A larger sample size would
allow for a stronger effect size and potentially the trends for LFnu and HFnu would be
statistically significant. However, the sample size was large enough to produce a
significant difference in LF-HF ratio.
In conclusion, people with OSA have lower HRV at rest which has been
confirmed by previous research. This study found a lower LF-HF ratio during steadystate exercise in the OSA group which may be caused by the blunted parasympathetic
response in this population. At rest, the OSA group had a lower starting HFnu variable
than the control group, though not statistically significant. The lack of parasympathetic
withdrawal in the OSA group could be the association to autonomic dysfunction. Future
research with a larger sample group of OSA subjects is necessary to confirm this
hypothesis.
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Table 1—Subject Characteristics
Characteristic
Age
AHI
ESS
Weight (kg)
BMI (kg2/m2)
Waist Circumference (cm)
Neck Circumference (cm)
Resting HR
SBP
DBP

OSA
(n = 10)
43.7 ± 12.2*
29.9 ± 23.5*
8.6 ± 5.6
103.4 ± 23.6*
34.3 ± 6.0*
108.9 ± 14.1*
42.9 ± 4.3*
73.9 ± 8.6
120.4 ± 8.4
78.0 ± 9.2

CONTROL
(n = 16)
25.6 ± 9.5
1.4 ± 1.5
9.4 ± 5.6
84.2 ± 11.5
28.9 ± 3.2
91.8 ± 9.3
36.4 ± 3.4
68.6 ± 7.8
117.1 ± 8.4
75.1 ± 8.0

P
< 0.05
< 0.05
0.71
< 0.05
< 0.05
< 0.05
< 0.05
0.12
0.34
0.41

Table 1. Data are presented as means ± Standard Deviation.
*p<0.05
AHI = apnea-hypopnea index; ESS = Epworth Sleepiness Scale; BMI = body mass index;
HR = heart rate; SBP = systolic blood pressure; DBP = diastolic blood pressure
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Table 2—Physical Activity (PA) Data
Measure of PA

OSA

CONTROL

IPAQ (MET-min/week)
Number of days/week of PA
Number of sedentary bouts/day
Time per sedentary bout (min)
Sedentary time/day (min)
Light PA (min)
Lifestyle PA (min)
Moderate PA (min)
Vigorous PA (min)
Very Vigorous PA (min)
Steps/day

1232.67 ± 1312.91
5.40 ± 0.52
17.82 ± 4.83
21.80 ± 3.16
586.62 ± 146.61
139.48 ± 70.03
75.15 ± 53.20
31.43 ± 16.74
1.66 ± 3.69
0.00 ± 0.00
5486.62 ± 2524.99

2395.82 ± 1329.72
5.07 ± 0.80
17.20 ± 6.14
21.32 ± 4.76
564.10 ± 161.05
137.64 ± 50.05
47.86 ± 17.36
30.45 ± 17.37
0.93 ± 1.32
0.05 ± 0.19
5478.24 ± 2037.97

Table 2. Data are presented as means ± Standard Deviation. No differences between
groups.
IPAQ = International Physical Activity Questionnaire
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Table 3—Sleep Data
Sleep Variable
Sleep Latency (min)
Sleep Efficiency (%)
Total Sleep Time (min)
Number of Awakenings
Avg. Length of Awakening (min) ǂ
Total Time in Bed (min)
Wake After Sleep Onset

OSA
4.96 ± 2.87
79.12 ± 10.92
362.89 ± 79.03
19.88 ± 7.09
5.07 ± 3.30
409.35 ± 25.92
69.17 ± 15.79

Table 3. Data are presented as means ± Standard Deviation.
* Significant, p<0.05
ǂ Data adjusted for age.

CONTROL
3.54 ± 3.82
88.36 ± 6.30
388.50 ± 55.79
14.90 ± 6.89
3.28 ± 1.03
470 ± 19.39
64.20 ± 12.02

P
0.328
0.013*
0.351
0.094
0.069
0.115
0.830
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Table 4—Oxygen Consumption
Measured Variables
VO2max prediction
Predicted 35% VO2R
Predicted 70% VO2R

OSA
28.0 ± 4.7
9.4 ± 2.3
18.4 ± 3.7

CONTROL
35.3 ± 4.4
11.4 ± 1.7
22.8 ± 3.3

P (intensity)
----

P (between groups)
<0.05*
<0.05*
<0.05*

Oxygen Consumption ǂ
Light Intensity
Vigorous Intensity
RER ǂ
Light Intensity
Vigorous Intensity
Systolic BP ǂ (mmHg)
Light Intensity
Vigorous Intensity
Diastolic BP (mmHg)
Light Intensity
Vigorous Intensity

17.26 ± 2.58°
23.98 ± 4.83°

18.03 ± 2.93°
26.45 ± 4.77°

0.00*

0.913

0.00*

0.702

0.88 ± 0.05
0.97 ± 0.04

0.89 ± 0.06
0.99 ± 0.05
0.00*

0.348

180.52 ± 21.0
198.79 ± 26.05

157.60 ± 17.97
173.87 ± 17.44
0.105

0.067

91.46 ± 11.38
94.22 ± 12.46

83.33 ± 9.28
84.80 ± 10.90

Table 4. Data are presented as means ± Standard Deviation.
* Significant, p<0.05
° Significantly higher than predicted oxygen consumption, p<0.001
ǂ Data adjusted for age.
VO2max = maximal oxygen consumption
RER = Respiratory exchange ratio
BP = Blood pressure
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Table 5—HRV Data
HRV Variable

Intensity
Rest¤

Light

SDNN(ms) *#
OSA
1.57 ± 0.31
0.80 ± 0.16
CONTROL
1.85 ± 0.29
1.05 ± 0.27
RMSSD(ms)*#
OSA
1.37 ± 0.27
0.49 ± 0.18
CONTROL
1.78 ± 0.37
0.45 ± 0.12
2
Total Power(ms )*°#
OSA
3.26 ± 0.65
1.82 ± 0.49
CONTROL
3.79 ± 0.57
2.24 ± 0.65
VLF(ms2)°#
OSA
3.02 ± 0.76
1.73 ± 0.53
CONTROL
3.44 ±0.56
2.17 ± 0.64
LFnu
OSA
52.36 ± 18.47
62.39 ± 20.81
CONTROL
40.32 ± 20.47
51.37 ± 22.54
HFnu
OSA
47.64 ± 18.47
37.51 ± 20.87
CONTROL
59.77 ± 20.47
27.32 ± 19.71
LF-HF Ratio(ms2)**
OSA
2.04 ± 0.35
2.25 ± 0.44
CONTROL
1.81 ± 0.40
2.51 ± 0.45
LF(ms2)ǂ#
OSA
2.51 ± 0.58
0.598 ± 0.36
CONTROL
3.03 ± 0.52
-0.16 ± 0.34
2
HF(ms )ǂ#
OSA
2.46 ± 0.45
0.34 ± 0.49
CONTROL
3.22 ± 0.70
0.65 ± 0.80
*p<0.05, significant difference at rest between groups
**p<0.05, significant main effect for group during exercise
#p<0.05, significant main effect for intensity during exercise
ǂ adjusted for age at rest.
° adjusted for age during exercise.
¤ rest data collected on a different day then exercise data.

Vigorous
0.67 ± 0.18
0.76 ± 0.41
0.59 ± 0.28
0.47 ± 0.25
1.28 ± 1.44
1.44 ± 0.86
1.24 ± 0.34
1.40 ± 0.86
72.66 ± 19.70
66.52 ± 18.26
48.17 ± 22.86
33.86 ± 18.10
2.03 ± 0.45
2.34 ± 0.39
1.15 ± 0.75
0.11 ± 0.86
-0.19 ± 0.49
-0.23 ± 0.82
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Figure 1—LFnu (A), HFnu (B), and LF-HF Ratio (C) between OSA and Control at rest,
light intensity, and vigorous intensity
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All figures presented as means ± SD.
*p<0.05, LF-HF ratio is significantly lower in the OSA group compared to the control group.
A. During exercise, LFnu is trending higher in the OSA group towards a main effect for group.
B. During exercise, HFnu is trending higher in the OSA group towards a main effect for group.
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James Madison University
Department of Kinesiology
Informed Consent
Purpose
You are being asked to volunteer for a research project conducted by Dr. Trent Hargens
from James Madison University entitled, “The effects of obstructive SLEEP apnea on
AUTONOMIC and cardiovascular FUNCTION during steady-state EXERCISE”, or
the SAFE study.
The primary goals of this study is to examine whether individuals who are newly
identified as high risk for, or diagnosed with, obstructive sleep apnea (OSA) have show
altered heart rate and cardiovascular variables during sub-maximal exercise. This may
provide a clearer picture into why OSA increases the risk for other chronic health
problems.
Experimental Procedures
You will be asked to visit the Human Performance Laboratory (HPL) in Godwin Hall 3
times over the course of about 7 – 10 days. Your total time commitment for participation
in this study will be approximately 2 and a half hours. In addition, you will be asked to
wear (for one night) an at-home sleep testing device (the ApneaLink) to screen you for
possible OSA. It is equipped with straps, a finger probe, and a nasal cannula. It
measures your breathing activity, heart rate, and blood oxygen levels, and is harmless to
wear. Also, you will be asked to wear a device (an accelerometer) on your waist during
the day for a period of 4 days, including 1 weekend day, while wearing the same device
on your wrist at night while you sleep. Detailed information on each visit is provided
below:
Visit 1
Before any test is given, you will be asked to complete a screening form and an informed
consent, to insure that you meet the study criteria, that you do not have any factors that
would disqualify you from participation. Upon completion of the informed consent, you
will be asked to complete a short health history questionnaire providing information
about your characteristics and health. You will then be asked complete 3 standardized
questionnaires about snoring, the quality of your sleep, daytime sleepiness, and risk for
OSA.
You will then have your height, weight, waist circumference and neck circumference
measured. After that, your body composition will be analyzed via a Dual-energy x-ray
absorptiometer (DEXA). The DEXA scan will allow us to measure your percent body fat
and the mineral content and density of your bones. The DEXA is much like an X-ray
machine. The DEXA will scan your entire body very slowly; so, you will need to lie on a
table without moving for almost 10 minutes, while the DEXA is passed over your entire
body. You will feel no discomfort associated with this test.
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At the end of this first visit you will also be instructed on the proper use procedures for
wearing the ApneaLink device for your one-night sleep assessment, as well as
instructions on wearing the accelerometer. An accelerometer is a small device that is to
be worn on your waist during the day and on your wrist while in bed.
Following the DEXA scan, we will ask that you wear a heart rate monitor while lying
down in a darkened room for 15 minutes to get measures of your heart rate. We will also
obtain your resting blood pressure.
Visit 2
The following day after Visit 1, you will be asked to return to the HPL to return the
ApneaLink device. Following this, we will ask that you wear a heart rate monitor while
lying down in a darkened room for 15 minutes to get measures of your heart rate. We
will also obtain your resting blood pressure. This visit should take about 30 minutes.
Visit 3
Approximately 5 – 6 days later, you will be asked to return to the HPL for your final
visit. For this visit you will undergo a submaximal treadmill exercise test. You will be
asked to walk on the treadmill for a total of about 15 minutes, which includes a 3 – 4
minute warm-up, and 2 – 3 minute cool-down. In between the warm-up and cool-down
you will be asked to walk at 2 separate workloads, 1 fairly easy, and 1 somewhat hard,
for 5 minutes at each workload. During this test we will monitor the electrical output of
your heart by placing electrodes directly on your skin across your chest, stomach and
back. A female researcher will be available to place and remove electrodes for female
subjects. During the test, we will measure the electrical activity of your heart, your heart
rate, blood pressure, your effort, and how much oxygen your body is using. To see how
much oxygen you use, we will ask you to breathe into a rubber mouthpiece. . During the
test, you will breathe only through the mouthpiece and may experience some dryness in
your mouth. Prior to your arrival to the HPL for this visit, you will be asked to consume
a normal meal (breakfast or lunch) and not to come to the HPL with a full stomach.
Risks
There are no risks associated with wearing an accelerometer. Also, there is no risk
associated with heart rate, blood pressure, height, weight, and waist and neck
circumference measures. You will not be asked to change any of your personal habits
during the course of the study. Measurements with associated risks include: the DEXA
scan and treadmill exercise test.
The amount of radiation that you will receive in the DEXA exam is less than the amount
you will receive during a transatlantic flight, and is equal to about 1/20 of a chest x-ray.
You should not be pregnant for this study because of risks from the DEXA scan radiation
to the embryo or fetus. If you feel that you might be pregnant, inform the research staff
immediately.
There is a risk of abnormal changes during the submaximal treadmill exercise test. These
changes may include abnormal blood pressure, fainting, heart rhythm disorders, stroke,
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heart attack, and death. The chance of serious heart problems during maximal exercise
among adults is very small (less than 1/10,000 maximal exercise tests). The exercise trial
for this proposed study is sub-maximal vs. maximal, so the risk for complications is even
less. Every effort will be made to minimize risks of an abnormal response by reviewing
you health history and providing adequate supervision of the exercise test. All staff are
certified by the American Heart Association in BLS (Basic Life Support).
Benefits
There is no guarantee that you will get any benefit from taking part in this study.
Benefits may include knowledge about your health status. You will receive information
on your body composition, including percent body fat and bone mineral density, an
assessment of your sleep quality and risk for sleep apnea, an assessment of your physical
activity level, and cardiovascular fitness. Indirect benefits of participating in this study
will be helping the researchers better understand the relationship between habitual
snoring, sleep apnea, and cardiovascular disease risk.
Inquiries
If you have any questions or concerns or you would like to receive a copy of the final
aggregate results of this study, please contact Dr. Trent Hargens at hargenta@jmu.edu or
(540) 568-5844.
Questions about Your Rights as a Research Subject
Dr. David Cockley
Chair, Institutional Review Board
James Madison University
(540) 568-2834
cocklede@jmu.edu
Confidentiality
All data and results will be kept confidential. You will be assigned an identification code.
At no time will your name be identified with your individual data. The researcher retains
the right to use and publish non-identifiable data. All data will be kept secured in a
locked cabinet. All electronic data will be kept on a password-protected computer. Final
aggregate results will be made available to participants upon request.
Freedom of Consent
Your participation is entirely voluntary. You are free to choose not to participate.
Should you choose to participate, you can withdraw at any time without consequences of
any kind.
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I have read this consent form and I understand what is being requested of me as a
participant in this study. I freely consent to participate. I have been given satisfactory
answers to my questions. The investigator provided me with a copy of this form. I
certify that I am at least 18 years of age.
_______________________________

___________________________________

Name of Subject (Printed)

Name of Researcher (Printed)

_______________________________

___________________________________

Name of Subject (Signed)

Name of Researcher (Signed)

_______________________________

___________________________________

Date

Date
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Epworth Sleepiness Scale

Subject ID____________________________________ Date Completed ____/____/____

This questionnaire asks you to indicate the chances of you becoming drowsy during
hours of the day that you are not in bed sleeping. “How likely are you to doze off or fall
asleep in the following situations?”

Use the following scale and indicate the most appropriate number for each situation.

0 = would never doze
1 = slight chance of dozing
2 = moderate chance of dozing
3 = high chance of dozing

Situation

Chance of Dozing

1.

Sitting and reading

_____

2.

Watching T.V.

_____

3.

Sitting, inactive in a public place
(ex. Theatre or meeting)

4.

As a passenger in a car for
an hour without a break

5.

_____

_____

Lying down to rest in the afternoon
when circumstances permit

_____

6.

Sitting and talking with someone

_____

7.

Sitting quietly after a lunch without alcohol

_____
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8.

In a car, while stopped for a few minutes in traffic

Sum of Scores, items 1-8

(staff use only)

_____

_____/24

54

Appendix C:

Berlin Questionnaire

55

Berlin Questionnaire
Subject ID____________________________________ Date Completed ____/____/____

Height (cm) ___________

Weight (kg) _________

Please choose the correct response to each question.
Category 1
1. Do You Snore?
☐ a. Yes
☐ b. No
☐ c. Don’t know

If you snore:
2. Your snoring is:
☐ a. Slightly louder than breathing
☐ b. As loud as talking
☐ c. Louder than talking
☐ d. Very loud – can be heard in
adjacent rooms
3. How often do you snore?
☐ a. Nearly every day
☐ b. 3-4 times a week
☐ c. 1-2 times a week
☐ d. 1-2 times a month
☐ e. Never or nearly never

Age _____
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4. Has your snoring every bothered
other people?
☐ a. Yes
☐ b. No
☐ c. Don’t Know
5. Has anyone noticed that you quit
Breathing during your sleep?
☐ a. Nearly every day
☐ b. 3-4 times a week
☐ c. 1-2 times a week
☐ d. 1-2 times a month
☐ e. Never or nearly never

Category 2
6. How often do you feel tired or fatigued after you sleep?
☐ a. Nearly every day
☐ b. 3-4 times a week
☐ c. 1-2 times a week
☐ d. 1-2 times a month
☐ e. Never or nearly never
7. During your waking time, do you feel tired, fatigued or not up to par?
☐ a. Nearly every day
☐ b. 3-4 times a week
☐ c. 1-2 times a week
☐ d. 1-2 times a month
☐ e. Never or nearly never
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8. Have you ever nodded off or fallen asleep while driving a vehicle?
☐ a. Yes
☐ b. No
If yes:
9. How often does this occur?
☐ a. Nearly every day
☐ b. 3-4 times a week
☐ c. 1-2 times a week
☐ d. 1-2 times a month
☐ e. Never or nearly never

Category 3
10. Do you have high blood pressure?
☐ a. Yes
☐ b. No
☐ c. Don’t Know
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STOP Questionnaire

Subject ID___________________________________ Date Completed ____/____/____
Height (Inches) ___________

Weight (lbs) _________

Age _____

Neck Circumference (cm) ____________
The STOP Test consists of four questions:
1. Snoring
Do you snore loudly (louder than talking or loud enough to be heard through closed
door)?
Yes No
2. Tired
Do you often feel tired, fatigued or sleepy during the day?

Yes No

3. Observed
Has anyone observed you stop breathing during your sleep?

Yes No

4. Blood Pressure
Do you have or are you being treated for high blood pressure?

High risk of OSA: answering yes to two or more questions
Low risk of OSA: answering yes to less than two questions

Yes No
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Medical and Health History Form

Name:

Date of Birth: ________________

Ethnicity:
Height:

ft

Weight:

Gender: Female

pounds
Male

Campus Address:
Campus Telephone Number: ____________________
Campus Email Address: _____________________
Address for Permanent Residence: ________________________________________________________
Person to contact in case of emergency: _____________________________________________________
Relationship: _____________
Primary Care Physician:

Daytime Telephone: ____________

________________________

Home Telephone:

Telephone:

Medical History
Please indicate any current or previous conditions or problems you have experienced or have been told by a
physician you have had:
Yes

No

Heart disease or any heart problems:

_____

_____

Rheumatic fever:

_____

_____

Respiratory disease or breathing problems:

_____

_____

Circulation problems:

_____

_____

Kidney disease or problems:

_____

_____

Urinary problems:

_____

_____

Reproductive problems:

_____

_____
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Musculoskeletal problems:

_____

_____

Fainting or dizziness, especially with exertion:

_____

_____

Neurological problems/disorders:

_____

_____

High blood pressure:

_____

_____

Low blood pressure:

_____

_____

High blood cholesterol:

_____

_____

Diabetes:

_____

_____

Thyroid problems:

_____

_____

Eating disorders (bulimia, anorexia):

_____

_____

Allergies:

_____

_____

If "yes" to any of the above please indicate the date, explain, and describe:

Please list any hospitalizations/operations/recent illnesses (Type/Date):

Do you ever feel faint, short of breath, or chest discomfort with exertion? Yes: ________ No: ________
If "yes", please explain :

Are there any orthopedic limitations you have that may restrict your ability to perform hard running
exercise or intense strength-type exercises? (back, hips, knees, ankles)
If "yes" please explain:

Yes

No _____
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Family Health History
Has anyone in your family (blood relatives only) been diagnosed or treated for any of the following?
Yes

No

Relationship

Age

Heart attack

_____

_____

_____

Heart disease

_____

_____

_____

High blood pressure

_____

_____

_____

Stroke

_____

_____

_____

Kidney disease

_____

_____

_____

Diabetes

_____

_____

_____

Health Habits
Do you add salt to your food? Yes ___ No ___ Are you on any special type of diet? Yes ___ No ___
If "yes" please describe

Do you drink caffeinated beverages? Yes _____ No ______
Do you drink alcoholic beverages?

Yes _____

How many cups per day?

No ______ How many drinks per week? _________

What is the average number of drinks that you consume on the weekend? _________
Did you use tobacco products in the past (more than 12 months ago)? Yes ______

No _______

Sleep Habits Evaluation
Do you have episodes of parasomnias (disorders such as sleep walking, sleep talking, night terrors, body
rocking, bedwetting that will cause partial or full awakening?) Yes

No

Do you show signs of sleep disturbances (such as insomnia, daytime sleepiness) when you are anxious,
stressed?

Yes

No

Do you have difficulties to fall asleep if a certain object or a certain situation is absent such as listening to
the radio, watching the television, etc?

Yes

No
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Do you have difficulties to fall asleep earlier or later of your usual bedtime? Yes
Do you wake up at night to get a little snack? Yes

No

No

If “yes”, do you think that the snack is helping you to go back to sleep? Yes

No

Do you have hallucinations (vivid images that look like dreams occurring when you sleep) or find yourself
physically weak or paralyzed for a few seconds?

Yes

No

Tonsils and Adenoids evaluation questionnaire
Do you have a history of recurrent tonsillitis which is an inflammation of the tonsils (clusters of tissue that
lie in bands on both sides of the back of the throat) caused by an infection? In tonsillitis, the tonsils are
enlarged, red, and often coated either partly or entirely? Yes

No

Did you ever have inflammation of the adenoids (single clump of tissue in the back of the nose) causing a
blockage of the back of the nose, chronic and recurrent fluid or infections of your ears, or chronic or
recurrent sinus infections?

Yes

No

Did you have tonsillectomy (tonsils removed) or adenoidectomy (adenoids removed)? Yes

No

Medications
Please list all medications (prescription and over-the-counter) you are currently taking or have taken in the
past week:

Please sign to indicate the above information is correct:

____
Print Name

Follow Up Review and Interview by:

Signature

Date

____________________________________
Signature of Project Staff Member

Date
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